KindlyMD (NASDAQ:NAKA) Price Target Raised to $11.00

KindlyMD (NASDAQ:NAKA) had its price target hoisted by B. Riley Financial from $9.00 to $11.00 in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently commented on NAKA. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. TD Cowen lifted their price target on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

KindlyMD Price Performance

Shares of NASDAQ NAKA opened at $8.13 on Thursday. KindlyMD has a 1-year low of $3.33 and a 1-year high of $343.20. The business has a fifty day moving average price of $5.21 and a 200 day moving average price of $6.94. The stock has a market capitalization of $145.53 million, a P/E ratio of -0.23 and a beta of 15.99.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The firm had revenue of $35.87 million for the quarter. As a group, equities research analysts anticipate that KindlyMD will post -12.87 earnings per share for the current fiscal year.

Insider Buying and Selling at KindlyMD

In other news, CEO David F. Bailey bought 32,134 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average price of $5.59 per share, with a total value of $179,629.06. Following the completion of the acquisition, the chief executive officer directly owned 32,134 shares of the company’s stock, valued at $179,629.06. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders bought 41,904 shares of company stock valued at $235,231 over the last quarter. 24.49% of the stock is currently owned by corporate insiders.

Institutional Trading of KindlyMD

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of KindlyMD in the fourth quarter worth $151,000. J. Derek Lewis & Associates Inc. purchased a new position in shares of KindlyMD during the 4th quarter valued at about $167,000. Truist Financial Corp purchased a new position in shares of KindlyMD during the 4th quarter valued at about $176,000. Waddell & Associates LLC acquired a new position in shares of KindlyMD in the 4th quarter valued at about $201,000. Finally, Invesco Ltd. acquired a new position in shares of KindlyMD in the 4th quarter valued at about $211,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.